On June 30, Jim Cramer told Mad Money viewers his favorite stock is a company most people wrote off two years ago. “Intel, ...
CNBC's Jim Cramer said Moderna's expanding pipeline in treatments for cancer and other diseases provides a compelling ...
Cramer blessed VYGR for a 23-year-old caller based purely on time horizon, not fundamentals, as the stock has dropped 69% over ten years. Analysts give VYGR 11 Buy ratings and a $15 average target, ...
CNBC's Jim Cramer details the ten stocks he missed out on last month and explains why he was wrong. Got a confidential news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results